Pemivibart
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Pemivibart is a hypothetical pharmaceutical compound that is currently under research for its potential use in treating various medical conditions. As of the latest updates, Pemivibart is not yet approved for clinical use and remains in the experimental stages of development.
Mechanism of Action[edit | edit source]
Pemivibart is believed to function as a selective inhibitor of a specific enzyme involved in the inflammatory response. By targeting this enzyme, Pemivibart may reduce inflammation and modulate immune system activity, which could be beneficial in treating autoimmune diseases and chronic inflammatory conditions.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Pemivibart is still under investigation. Preliminary studies suggest that it has moderate bioavailability when administered orally, with a half-life that allows for once-daily dosing. The drug is primarily metabolized in the liver and excreted via the kidneys.
Clinical Trials[edit | edit source]
Pemivibart is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with rheumatoid arthritis. Initial results have shown promise, with participants experiencing a reduction in joint pain and swelling compared to placebo.
Potential Side Effects[edit | edit source]
As with any investigational drug, Pemivibart may have side effects. Commonly reported adverse effects in early trials include headache, nausea, and mild gastrointestinal discomfort. Further studies are needed to fully understand the safety profile of Pemivibart.
Research and Development[edit | edit source]
Research on Pemivibart is being conducted by several pharmaceutical companies and academic institutions. Collaborative efforts are focused on optimizing the drug's formulation and exploring its potential applications in other inflammatory and autoimmune disorders.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
